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Abstract
Bacteria are the leading cause of infections after solid organ transplantation. In recent years, a progressive growth in the incidence of
multidrug-resistant (MDR) and extensively-drug-reistant (XDR) strains has been observed. While methicillin-resistant Staphylococcus aureus
(MRSA) infection is declining in non-transplant and SOT patients worldwide, vancomycin-resistant enterococci, MDR/XDR Enterobac-
teriaceae and MDR/XDR non-fermenters are progressively growing as a cause of infection in solid organ transplant (SOT) patients and
represent a global threat. Some SOT patients develop recurrent infections, related to anatomical defects in many cases, which are difﬁcult to
treat and predispose patients to the acquisition of MDR pathogens. As the antibiotics active against MDR bacteria have several limitations
for their use, which include less clinical experience, higher incidence of adverse effects and less knowledge of the pharmacokinetics of the
drug, and, in most cases, are only available for parenteral administration, it is mandatory to know the main characteristics of these drugs to
safely treat SOT patients with MDR bacterial infections. Nonetheless, preventive measures are the cornerstone of controlling the spread of
these pathogens. Thus, applying the Center for Disease Control and Prevention’s and the European Society of Clinical Microbiology and
Infectious Diseases’s recommended antibiotic policies and strategies to control the transmission of MDR strains in the hospital setting is
essential for the management of SOT patients.
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Hot Topics
 A bacterial strain is deﬁned as multidrug resistant (MDR)
when it is not susceptible to one or more agents in three
or more antimicrobial categories active against the isolated
bacteria.
 To prevent the acquisition of MDR strains during hospital-
ization, the procedures recommended by the Center for
Disease Control and Prevention (CDC) and the European
Society of Clinical Microbiology and Infectious Diseases
(ESCMID) guidelines should be applied.
 In addition to antibiotic treatment, which is unavoidable in
most solid organ transplantation (SOT) recipients, certain
features related to the surgical technique of the transplan-
tation alter the risk of bacterial infection.
 While methicillin-resistant Staphylococcus aureus (MRSA)
infection is declining in non-transplant and SOT patients
worldwide, vancomycin-resistant enterococci, MDR/exten-
sively-drug resistant (XDR) Enterobacteriaceae and MDR/
XDR non-fermenters are progressively growing as a cause of
infection in SOT patients and represent a global threat.
 Some SOT patients develop recurrent infections, related to
anatomical defects in many cases, which are difﬁcult to treat
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and predispose patients to the acquisition of MDR patho-
gens.
 The antibiotics active against MDR bacteria have several
limitations for their use, which include less clinical experi-
ence, higher incidence of adverse effects and less knowl-
edge of the pharmacokinetics of the drug, and, in most
cases, are only available for parenteral administration. It is
mandatory to know the main characteristics of these
drugs to safely treat SOT patients with MDR bacterial
infections.
Main Characteristics of MDR Bacterial
Infection after SOT
Recommendations
 To prevent the acquisition of MDR strains during hospital-
ization, the procedures recommended by the CDC should
be applied (A-I).
 For empirical treatment of suspected bacterial infections in
SOT patients, the selection of antimicrobial agents should be
based on local epidemiological data and on the patient’s
history of colonization or infection with antibiotic-resistant
organisms (A-II).
General principles, deﬁnitions and risk factors for MDR
bacterial infection after solid organ transplantation
Bacteria are the leading cause of infections after solid organ
transplantation (SOT). After the surgical procedure, transplant
patients should remain in the hospital for a period of time,
which varies according to the type of allograft, previous
existence of co-morbidities, the underlying disease responsible
for transplantation and the development of complications.
During prolonged hospitalization, most patients receive
broad-spectrum antibiotics and some develop infections with
multidrug-resistant (MDR) bacteria. The use of central line and
urinary catheters, parenteral nutrition and prolonged intuba-
tion and the need for renal replacement therapy all increase
the risk of this complication.
The most widely accepted deﬁnition of MDR includes lack
of susceptibility to one or more agents in three or more
antimicrobial categories active against the isolated bacteria
(Table 1) [1]. In the case of S. aureus, methicillin resistance on
its own deﬁnes the strain as MDR, regardless of resistance to
other antimicrobials. Many transplant patients may be infected
with extensively-drug resistant (XDR) bacteria, which is
deﬁned as susceptibility to no more than two classes of active
categories of antimicrobials (Table 1) [1]. In recent years,
certain bacterial strains have shown a lack of susceptibility to
all the active drugs for treating the microorganism; in this case,
the isolated bacterium is deﬁned as pan-drug resistant (PDR).
A group of six organisms representing the paradigm of
pathogenesis, transmission and potential antibiotic resistance
have been recently deﬁned and labeled as the ESKAPE
pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsi-
ella pneumoniae, Acinetobacter baumannii, Pseudomonas aerugin-
osa and Enterobacter spp.) [2,3]. As identifying novel
antimicrobial agents with reliable activity against these patho-
gens is very difﬁcult, special efforts to identify optimal
strategies for infection control and antimicrobial use are
warranted.
Multidrug-resistant organisms lead to increased use of
hospital resources due to extended hospital stays, more
frequent physician consultations and laboratory tests, and
costly medications [4]. Speciﬁcally, their presence increases
the costs derived from solid organ transplantation (SOT). In
addition, MDR bacterial infection jeopardizes patient and graft
survival. Infection is the second leading cause of death in renal
transplant recipients, and the incidence of mortality related to
bacterial infection in this group of patients has remained stable
over the last decade [5]. Approximately 14% of patients with
renal transplantation develop an infectious episode caused by
MDR bacteria in the post-transplant period, including enteric
Gram-negative bacilli, non-fermentative Gram-negative bacilli,
enterococci and S. aureus [6]. This complication is associated
with poorer graft and patient survival [6]. One of the greatest
dangers when treating an SOT patient with fever and risk of
MDR bacterial infection is the use of inappropriate empirical
antibiotic therapy. Several studies have demonstrated an
increase in mortality when bacteraemic patients with MDR
pathogens receive inappropriate treatment [7,8]. In one
retrospective cohort study evaluating empirical antibiotic
therapy in SOT patients, inappropriate antibiotic therapy
was administered to 54% of patients, resulting in a 3.5-fold
increase in mortality compared with those receiving ade-
quate therapy [9]. Therefore, in order to initiate appropriate
antibiotic therapy it is important to know the local rates of
antimicrobial resistance. Early therapy may also reduce the
mortality associated with severe sepsis and septic shock,
which occur in nearly 15% of bacteraemic infections in SOT
recipients and have a mortality rate of 50% [10].
There are two main strategies for the prevention of MDR
transmission in the hospital [11]. Vertical infection-prevention
strategies are designed to reduce colonization or infection
due to a speciﬁc pathogen; they involve a microbiological
screening test and carry high resource utilization, direct costs
and opportunity costs [12]. Horizontal strategies are
population-based, applied universally, and use interventions
effective in controlling all pathogens transmitted by means of
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the same mechanism. Horizontal interventions include hand
hygiene, chlorhexidine bathing and care bundles [11]. In the
transplant population, as the risk of acquiring MDR pathogens
is higher than in other hospitalized patients, both strategies
are probably required to control the spread of these
microorganisms. During admission the international recom-
mendations for infection control should be followed (appro-
priate hand washing, contact isolation, antibiotic policy, and
so on). In the case of catheter-related bacteraemia, the
application of the evidence-based procedures recommended
by the CDC [13] (hand-washing, the use of full-barrier
precautions during the insertion of central venous catheters
avoiding the femoral site, cleaning the skin with chlorhexi-
dine, and removing unnecessary catheters) has been shown
to diminish the risk of catheter-related bacteraemia [14]. In
addition, improved hand hygiene plus unit-wide chlorhexidine
body-washing reduces acquisition of antimicrobial-resistant
bacteria in the intensive care unit [15]. Here, vertical
prevention strategies for each MDR microorganism will be
discussed. Finally, limiting unnecessary uses of antimicrobial
agents through multidisciplinary stewardship programmes is
critical to minimize the emergence of MDR bacteria in solid
organ transplant patients, as has been proved in non-trans-
plant hospitalized patients.
Multidrug-resistant infections can be acquired by the
recipient through the donor’s graft in the setting of organ
transplantation. Although this issue is addressed in another
chapter of this monograph, it should be noted that
transmission of MDR bacteria through the donor may be
difﬁcult to diagnose, leading to delayed treatments and high
mortality. Proper diagnosis and treatment of a donor’s
infection and accurate screening of the preservation ﬂuid for
bacterial or fungal colonization is essential to prevent this
complication.
Another important point is the fact that MDR strains have
to be treated with second- or third-line antibiotics, the use of
TABLE 1. Deﬁnitions of multidrug-resistant (MDR), extensively-drug-resistant (XDR) and pan-drug-resistant (PDR) bacteria
(adapted from Magiorakos et al. [1])
S. aureus Enterococcus spp. Enterobacteriaceae P. aeruginosa
Active agents: Antimicrobial
category (agents)
 Aminoglycosides
(gentamicin)
 Ansamycins (rifampin/
rifampicin)
 Cephalosporins (ceftaroline)
 Anti-staphylococcal
b-lactams (oxacillin)
 Cephamycins (cefoxitin)
 Fluorquinolones (cipro/
moxiﬂoxacin)
 Folate pathway inhibitors
(sulfamethoxazole-
trimethoprim)
 Fucidanes (fusidic acid)
 Glycopeptides (vancomycin,
teicoplanin, telavancin)
 Glycylcyclines (tigecycline)
 Lincosamides (clindamycin)
 Lipopeptides (daptomycin)
 Macrolides (erythromycin)
 Oxazolidinones (linezolid)
 Phenicols (chloramphenicol)
 Phosphonic acids
(fosfomycin)
 Streptogramins
(quinupristin-dalfopristin)
 Tetracyclines (tetracycline,
doxycycline, minocycline)
Active agents: Antimicrobial
category (agents)
 Aminoglycosides, except
streptomycin (high-level
resistance gentamicin)
 Streptomycin (high-level
resistance streptomycin)
 Carbapenems (imipenem,
meropenem, doripenem)
 Fluorquinolones (ciproﬂoxa
cin, levoﬂoxacin,
moxiﬂoxacin)
 Glycopeptides (vancomycin,
teicoplanin)
 Glycylcyclines (tigecycline)
 Lipopeptides (daptomycin)
 Oxazolidinones (linezolid)
 Penicillins (ampicillin)
 Streptogramins
(quinupristin-dalfopristin)
 Tetracycline (doxycycline,
minocycline)
Active agents: Antimicrobial category (agents)
 Aminoglycosides (gentamicin, tobramycin,
amikacin, netilmicin)
 Anti-MRSA cephalosporins (ceftaroline)
 Anti-pseudomonal penicillins + b-lactamase
inhibitors (ticarcillin-clavulanic acid,
piperacillin-tazobactam)
 Carbapenems (imipenem, meropenem,
ertapenem, doripenem)
 Non-extended spectrum cephalosporins;
1st and 2nd generation cephalosporins
(cefazolin, cefuroxime)
 Extended-spectrum cephalosporins; 3rd and
4th generation cephalosporins (cefotaxime,
ceftriaxone, ceftazidime, cefepime)
 Cephamycins (cefoxitin, cefotetan)
 Fluorquinolones (ciproﬂoxacin)
 Folate pathway inhibitors
(sulfamethoxazole-trimethoprim)
 Glycylcyclines (tigecycline)
 Monobactams (aztreonam)
 Penicillins (ampicillin)
 Penicillins + b-lactamase inhibitors
(amoxicillin-clavulanic acid, ampicillin-
sulbactam)
 Phenicols (chloramphenicol)
 Phosphonic acids (fosfomycin)
 Polymyxins (colistin)
 Tetracyclines (tetracycline, doxycycline,
minocycline)
Active agents: Antimicrobial
category (agents)
 Aminoglycosides
(gentamicin, tobramycin,
amikacin, netilmicin)
 Anti-pseudomonals
carbapenems (imipenem,
meropenem, doripenem)
 Anti-pseudomonals
cephalosporins
(ceftazidime, cefepime)
 Anti-pseudomonals
ﬂuorquinolones
(ciproﬂoxacin, levoﬂoxacin)
 Anti-pseudomonal
penicillins + b-lactamase
inhibitors (ticarcillin-
clavulanic acid,
piperacillin-tazobactam)
 Monobactams (aztreonam)
 Phosphonic acids
(fosfomycin)
 Polymyxins (colistin
polymyxin B)
Criteria for multidrug-resistant (MDR): non-susceptible to ≥1 agent in ≥3 antimicrobial categories or methicillin resistance in the case of S. aureus. Criteria for extensively
drug-resistant (XDR): non-susceptible to ≥1 agent in all but ≤2 categories. Criteria for pan-drug-resistant (PDR): non-susceptible to all the antimicrobials.
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which tends to present major difﬁculties. First, physicians have
less experience with their use. Second, the incidence of
adverse effects is high (renal toxicity in the case of aminogly-
cosides and colistin, neurological toxicity in the case of colistin,
etc.). Third, they are available only in parenteral formulations
(usually accompanied by a prolonged hospital stay due to the
impossibility of discharge). In general, little is known about the
pharmacokinetics and pharmacodynamics of these second-line
drugs. In addition, as in many cases the serum levels of the drug
cannot be monitored, dosing has to be based on data obtained
from clinical cohorts. The incidence of adverse effects using
second-line antibiotics may be increased in SOT patients
because of the concomitant use of nephrotoxic agents (such
as calcineurin inhibitors), decreased glomerular ﬁltration
rate in most SOT patients, or because of the need for renal
replacement therapies. Finally, infection with MDR patho-
gens increases the length of hospitalization [16], which in
turn increases the risk of additional hospital-acquired
infections.
Main principles of the microbiological diagnosis of MDR
bacterial infections in SOT patients
In order to optimize the management of patients with
bacterial infection the isolation of the responsible strain is
important, and in organ transplant patients with a suspected
infection with an MDR pathogen this is mandatory. This will
allow not only its identiﬁcation and the study of antimicrobial
susceptibility, but also the obtaining of information on
epidemiological molecular markers. The majority of MDR
bacteria implicated in SOT infections (Table 1) usually grow in
ordinary culture media at a temperature of 37°C, in a
conventional aerobic atmosphere.
The determination of the MDR phenotype is inferred from
the data regarding sensitivity to various antibiotics, using highly
standardized methods such as disk diffusion, antibiotic gradient
strips (such as E-test), agar dilution and microdilution, usually
by automated processes. Among the most important break-
points used in the interpretation of antimicrobial susceptibility
are those indicated by the Clinical and Laboratory Standards
Institute (CLSI) and the European Committee on Antimicrobial
Susceptibility Testing (EUCAST).
Proteomics-based methods have recently emerged in
microbiology laboratories, improving the microbiological diag-
nosis of isolates. One of the most widely used techniques in
proteomics is mass spectrometry, a technique used to analyse
the precise chemical composition of different elements by
measuring their molecular ions, separating them according to
their mass/charge. The acronym MALDI-TOF is derived from
the terms matrix-assisted laser desorption/ionization and time
of ﬂight. One of its main applications is the identiﬁcation of
microorganisms. At present there are different MALDI-TOF
platforms for microbial identiﬁcation. Most conventional
bacteria responsible for human diseases are very accurately
identiﬁed by MALDI-TOF systems, which also identify multi-
drug-resistant isolates. The main advantage over conventional
phenotypic methods is the ability to obtain rapid diagnosis,
capable of identifying species within minutes.
An additional issue in the diagnosis of infection with MDR
organisms is the possibility of heteroresistance, deﬁned as the
presence of mixed populations of drug-resistant and drug-sen-
sitive strains in a single clinical specimen. Staphylococcus aureus
is the species in which heteroresistance has been described
more often, especially to vancomycin [17]. Heteroresistance
has been described also for vancomycin in E. faecium [18],
colistin and meropenem in carbapenemase-producing K. pneu-
moniae [19,20], polymyxin-B in carbapenem-resistant P. aeru-
ginosa [21] and colistin in A. baumanii [22], among others. The
clinical consequences of heteroresistance have been mainly
evaluated for heteroresistant vancomycin-intermediate
S. aureus, which is associated with prolonged bacteraemia
duration, greater rates of complications, and emergence of
rifampin resistance [23]. The reference standard for the
diagnosis of heteroresistance requires a population analysis
proﬁle, which is labour intensive, costly and unsuitable for
routine use in daily practice. Other techniques for diagnosis
are being evaluated to improve the practicability of heterore-
sistance diagnosis [24].
Surgical features according to type of allograft and their
involvement in the development of MDR infection
Most SOT patients require central venous lines, urinary
catheterization, abdominal drainages or mechanical venti-
lation, which are all sources of bacterial infection. In
addition, the use of broad-spectrum antibiotics is unavoid-
able in the majority of patients. All these issues are
common to all SOT recipients. However, certain features
related to the surgical technique alter the risk of bacterial
infection after SOT.
Renal grafts are usually implanted in the iliac fossa without
removing the native kidneys and the ureter is directly
connected to the native bladder. Urinary tract infection is
the most common infectious complication after renal trans-
plantation. After the procedure, urine ﬂow alterations may
develop because of ureteral stenosis or vesicoureteral reﬂux.
In addition, some renal transplant patients have underlying
urological abnormalities (e.g. neurogenic bladder or chronic
vesicoureteral reﬂux) that increase the risk of post-transplant
urinary tract infection. There are three types of kidney donor:
living, deceased and cardiac death (non-heart-beating). Renal
transplantation from cardiac-death donors develop delayed
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graft function more frequently than other types of renal
transplantation [25], which in turn increases the need for
dialysis and the incidence of infection [26].
The liver graft is usually placed orthotopically, as hetero-
topic liver transplantation is associated with worse outcome at
1 year [27]. As in the case of renal transplantation, liver grafts
may come from deceased, cardiac-death or living donors.
Living donor livers are used in adult-to-adult right lobe liver
transplantation, which is more frequently associated with
biliary complications such as leaks and anastomotic and
non-anastomotic strictures [28]. Liver transplantation from
cardiac-death donors has an increased risk of ischaemic
cholangiopathy [29]. Both living donor and cardiac-death
donor liver transplantation have an increased risk of bile
infections. Bile reconstruction after liver transplantation can be
performed in three ways: duct-to-duct reconstruction (by far
the most frequent one), choledoco-jejunostomy and hepati-
co-jejunostomy. Bile reconstructions other than duct-to-duct
carry a higher risk of bile infections and peritonitis [30].
Regarding pancreas transplantation, simultaneous kid-
ney-pancreas transplantation from a deceased donor is the
most frequent technique used for young diabetic patients with
end-stage renal failure. Exocrine drainage of the donor’s
pancreas is made through a duodenal stump from the donor
that can be drained to the jejunum (intestinal drainage) or to
the bladder (bladder drainage). Bladder drainage is associated
with a higher risk of infection than intestinal drainage [31]. As
pancreas transplantation involves intestinal manipulation, the
risk of peritonitis and abdominal collections is high.
Small bowel transplantation (intestinal transplantation) is
the treatment of choice in patients with intestinal failure and
complications of parenteral nutrition. Many of the patients
who undergo intestinal transplantation will have a heavily
scarred abdominal wall from multiple abdominal procedures
and previous bowel resections, which may cause technical
difﬁculties during surgery and complications later on. Very
often, small bowel and liver transplantation are combined
when irreversible liver damage develops due to long-term
parenteral nutrition. The small bowel is rich in lymphoid tissue,
which increases the risk of allograft rejection. Patients
undergoing small-bowel transplantation have a higher inci-
dence of infectious complications than other SOT recipients
because of a very high load of microorganisms in the intestinal
graft and because they require higher degrees of immunosup-
pression [32,33]. Intra-abdominal abscesses also occur often as
a consequence of bacterial translocation or peritoneal con-
tamination during surgery [34].
Heart grafts are placed orthotopically and, for obvious
reasons, always come from heart-beating deceased donors.
Surgical anatomy does not predispose heart transplant recip-
ients to higher risk of infectious complications, as the heart
graft does not come into contact with the environment.
However, the surgical technique requires performance of a
sternotomy, which can be complicated by postoperative
mediastinitis.
Forms of lung transplantation comprise basically dou-
ble-lung (sequential or in-block), single lung or double
heart-lung transplantation. The most frequent site of infection
is the lung, as the graft is exposed to the environment through
the airway. Bacteria are the most frequent pathogens causing
respiratory infections after lung transplantation, but environ-
ment-acquired tracheobronchial aspergillosis and aspergillosis
of the bronchial anastomosis are other complications related
to the anatomy of lung transplantation [35].
MDR Pathogens in Solid Organ Transplant
Recipients
Recommendations for the management of MRSA in
solid organ transplant patients
 Pre-transplant screening for MRSA nasal carriage and
decolonization with mupirocin in carriers is recommended
prior to transplantation in areas with low or moderate
prevalence of MRSA (B-II).
 Universal decolonization with nasal mupirocin should be
considered along with daily bathing with chlorhexi-
dine-impregnated cloths during the ICU stay after trans-
plantation in areas with high prevalence of MRSA (A-I).
 Vancomycin or daptomycin are the recommended drugs for
the treatment of MRSA bacteraemia with vancomycin
minimum inhibitory concentration (MIC) of 1.0 mg/L or
below (A-I).
 For the treatment of MRSA bacteraemia with vancomycin
MIC >1.0 mg/L, the use of daptomycin (B-I) or antibiotic
combinations with daptomycin is recommended in cases in
which bacteraemia persists during monotherapy (B-II).
Gram-positive bacteria
Methicillin-resistant Staphylococcus aureus. Multidrug resistance
is deﬁned for S. aureus by the existence of methicillin
resistance or lack of susceptibility to ≥1 active agent in ≥3
antimicrobial categories (Table 1). However, most epidemio-
logical studies focus on methicillin-resistant S. aureus (MRSA),
which represents almost all studies of multidrug resistance of
S. aureus.
Although S. aureus is the second most important aetiolog-
ical cause of bacteraemia in the population [36] and the leading
cause of nosocomial bacteraemia in Europe [37], in invasive
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infections in solid organ transplant recipients it falls to sixth
place [38]. In addition, the rate of methicillin resistance among
S. aureus isolates has been decreasing in recent years in Europe
[39] and in the United States [40]. Nevertheless, the occur-
rence of invasive S. aureus infection in organ transplant
patients is associated with very high mortality [41].
The most frequent source of S. aureus infections is nasal
colonization. Between 20 and 30% of healthy adults are
colonized and are persistent or intermittent carriers of
S. aureus [42], and 1.5–3.0% are persistently colonized with
MRSA [43–45]. In patients undergoing organ transplantation,
the prevalence of MRSA nasal carriage may be higher due to
permanent contact with healthcare resources (dialysis, hos-
pital admissions, etc.). One study found a prevalence of
S. aureus nasal colonization in patients undergoing liver
transplantation of 44% (9 out of 21 strains were MRSA),
with a 30% prevalence of MRSA nasal carriage [46]. Another
study demonstrated that MRSA colonization after liver
transplantation is not unusual and occurred in 15% of
patients who were not colonized prior to transplantation
[47]. In addition to nasal colonization, intestinal carriage of
S. aureus can be a potential source of infection; the preva-
lence of MRSA intestinal colonization varies in different
studies from 5 to 33% [48]. Intestinal carriage may increase
the risk of MRSA infection. In one study performed in
intensive care and liver transplant units, patients with both
nasal and intestinal colonization had signiﬁcantly increased
rates of S. aureus infection (40%) compared with patients with
nasal but not intestinal carriage (18%) [49]. In organ
transplant patients, nasal colonization is, however, the main
risk factor for MRSA infection in the post-transplant period
[50,51]. Patients who underwent a liver transplantation with
MRSA nasal colonization had an almost 16-fold higher risk of
infection with this bacterium, although the presence of nasal
colonization was not associated with an increase in mortality
[52]. In a surveillance study of liver transplant recipients with
nasal carriage of MRSA, the rates of infection decreased from
40.4% to 4.1% and the rate of bacteraemia from 25.5% to
4.1% after decolonization with topical mupirocin [53]. How-
ever, the results of this control strategy are controversial,
and one study did not ﬁnd a decrease in MRSA infection in
patients with nasal colonization with mupirocin-susceptible
strains treated with topical mupirocin, mainly because of
recolonization [46].
The spectrum of MRSA infection in solid organ transplant
patients mainly includes bacteraemia (catheter-related or
primary), surgical-site infection and pneumonia. Other sites
of infection are less frequent. As mentioned above, S. aureus
was found to be the sixth leading pathogen causing bactera-
emia in solid organ transplant patients in a Spanish study
performed in 16 hospitals [38]. Around 16% of the isolates
were resistant to methicillin and MRSA bacteraemia did not
have a worse prognosis [38]. In a multicentre study in Spain,
MRSA was the second cause of incisional surgical-site infection
after heart transplantation [54]. However, in other types of
transplantation such as kidney [55] or liver [56], S. aureus has
declined as a causative pathogen of surgical-site infection, in
which Gram-negative bacilli predominate. Staphylococcus aureus
is a frequent cause of pneumonia in solid organ transplant
patients [35]. In a single-centre study including mainly
non-pulmonary solid organ transplant patients, S. aureus was
the leading bacterium, representing 16% of all isolations, of
which 81% were MRSA [57]. In lung transplantation patients,
S. aureus is the leading cause of low-tract respiratory infection.
In one study, mortality due to MRSA infection in lung
transplant patients reached 23.5% [58].
To prevent MRSA transmission in hospital wards, several
strategies have been implemented and tested. Hand hygiene,
active surveillance and decolonization and patient isolation are
the most accepted. Staff hand hygiene compliance appears to be
the most successful strategy for reducing the prevalence and
incidence of MRSA [59–61]. Mathematical models suggest that
isolation of patients carryingMRSA in single-bed rooms could be
efﬁcacious in reducing the incidence of MRSA infection [62,63].
However, in one study performed in several ICUs with a high
prevalence of MRSA, universal decolonization was more effec-
tive than active surveillance and isolation and targeted decolo-
nization in reducing the number of infections with MRSA [64].
Table 2 summarizes the recommendations for infection control
in patients with MRSA colonization or infection.
The guidelines for the treatment of MRSA bacteraemia and
endocarditis in the general population state that vancomycin is
the treatment of choice [65,66]. However, daptomycin has
been shown to be non-inferior to the comparator (vancomycin
or betalactam) for the treatment of S. aureus bacteraemia or
endocarditis [67] and is less nephrotoxic. Recently, several
studies have shown that a higher vancomycin minimum
inhibitory concentration (MIC) confers a worse prognosis
for MRSA bacteraemia [68,69]. For the treatment of MRSA
with a high vancomycin MIC (>1.0 mg/L), the early use of
daptomycin reduced 30-day mortality and persistent bacter-
aemia compared with vancomycin [70]. Some cases of
persistent bacteraemia by MRSA, which did not clear by
switching to daptomycin with or without gentamicin, were
cured with the combined use of daptomycin plus antistaphy-
lococcal b-lactams [71]. This synergistic effect seems to be
achieved by a seesaw effect on daptomycin MIC induced by the
use of antistaphylococcal b-lactams [72], increasing the
incorporation of daptomycin in the S. aureus cellular wall
[71]. Finally, the combination of daptomycin plus fosfomycin
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20 (Suppl. 7), 49–73
54 Clinical Microbiology and Infection, Volume 20 Supplement 7, September 2014 CMI
is a promising alternative for refractory cases of MRSA
bacteraemia and/or endocarditis [73]. For the treatment of
non-bacteraemic MRSA infections, vancomycin is the drug of
choice. It has been suggested that linezolid could improve the
prognosis of MRSA pneumonia in comparison to vancomycin.
However, a recently published meta-analysis found similar
outcomes with the two drugs [74].
Vancomycin-resistant enterococci.
Recommendations for the management of vancomy-
cin-resistant enterococci in solid organ transplant
patients
 Routine screening for vancomycin-resistant enterococci
(VRE) in areas of low or moderate prevalence of these
strains is not recommended. However, during outbreaks or
in areas with high prevalence of VRE, active surveillance for
VRE colonization in SOT patients may be indicated (B-III).
 In patients known to be colonized with VRE, isolation in a
single-bed room and implementation of contact precautions
are indicated (B-II).
 Decolonization treatment for VRE-colonized patients is not
recommended (D-II).
 The use of linezolid is recommended for the treatment of
bloodstream infection with ampicillin-resistant VRE or with
VRE in patients with allergy to penicillin (B-II).
 For monomicrobial non-bacteraemic VRE infections in SOT
patients, the use of either linezolid or quinupristin-dalfopri-
stin is recommended, or daptomycin when the infection
does not involve the lung (B-III).
Enterococci are an emerging cause of infection in
solid organ transplant recipients. Vancomycin resistance in
enterococci occurs more frequently due to the acquisition of
either Van-A or Van-B genes/phenotype and it has been
described for both E. faecalis and E. faecium [75]. The clinical
relevance of vancomycin resistance to E. faecium is consider-
ably greater, as most strains are resistant to the b-lactams that
are active against E. faecalis. The Van-C phenotype is intrinsic
for both E. gallinarum and E. casseliﬂavus, and Van-D and Van-E
are highly infrequent in clinical practice [75].
While the overall prevalence of VRE in the United States
reached 33% in 2006–2007 [76], in Europe there is a huge
variation between countries in the prevalence of VRE.
Countries such as Norway, Finland, Iceland, Sweden, Nether-
lands, Belgium, France and Spain reported an incidence lower
than 5% in 2012, while in other countries such as Portugal and
Ireland, the prevalence of vancomycin resistance among
E. faecium isolates was higher than 20% (http://www.ecdc.
europa.eu/en/healthtopics/antimicrobial_resistance/database/
Pages/graph_reports.aspx, accessed April 27, 2004).
The clinical spectrum of VRE in organ transplant patients
includes urinary tract infection, infected bilomas, intra-abdom-
inal abscesses, surgical-site infection, bacteraemia and, rarely,
endocarditis. Most infections by VRE occur in previously
colonized patients. Liver transplant recipients with pre-trans-
plant colonization of vancomycin-resistant enterococci have an
almost four-fold increased risk of infection by these bacteria,
and colonization doubles the risk of mortality [52]. VRE
infection in liver transplant patients is associated with worse
outcome and a higher risk of re-transplantation, hepatic artery
thrombosis, biliary leak, haemodialysis and death [77,78].
Routine screening for VRE is not recommended in areas of
low or moderate prevalence of VRE [77]. However, during
outbreaks or in areas with high prevalence of VRE, active
TABLE 2. Summary of the infection control policies recommended when managing SOT patients with MDR infections
Contact
precautions
Isolation
room
Screening
cultures Decolonization
Environment
cleaning
Methicillin-resistant S. aureus Recommended Recommended Recommended prior
to transplantation
Consider clorhexidin
bathing in areas of high
prevalence during ICU stay
Consider nasal mupyrocin
for colonized patients in
conventional wards
Recommended
Vancomycin-resistant enterococci Recommended Recommended Only recommended
during outbreaks or
in areas with high
prevalence of VRE
Not recommended Recommended
ESBL-producing E. coli Recommended Not recommended Not recommended Not recommended Recommended
during outbreaks
and optional when
infections are epidemic
ESBL or ampC-producing
Enterobacteriaceae (other than
ESBL-producing E. coli)
Recommended Recommended Not recommended Not recommended Recommended
KPC-producing K. pneumoniae Recommended Recommended Recommended Not recommended Recommended
MDR/XDR non-fermentative
Gram-negative bacilli
Recommended Recommendeda Recommended prior
to lung transplantation
Not recommended
for other SOT
Not recommended Recommended
aIsolation room is not routinely recommended for patients infected or colonized with MDR/XDR B. cepacea.
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surveillance for VRE colonization may be indicated, as the
implementation of isolation and contact precautions has been
shown to reduce the incidence of VRE bacteraemia [79].
Isolation of VRE-colonized patients and the implementation of
contact policies have been shown to be effective for the
control of nosocomial transmission of VRE [80,81]. As
colonization with VRE can persist for weeks or months [82]
and many patients who spontaneously decolonize reacquire
VRE colonization [83,84], SOT patients previously colonized
with VRE requiring hospital readmission should be considered
colonized and isolated in a single-bed room (Table 2). Several
antibiotic regimens have been tried for VRE decolonization,
including bacitracin, gentamicin, tetracycline, doxycycline,
novobiocin, rifampicin and ramoplanin, with different rates of
efﬁcacy [85]. The most promising option is ramoplanin, but in
an experimental model of VRE colonization in mice its use
increased the density of indigenous Enterobacteriaceae and
overgrowth of an exogenously administered Klebsiella pneu-
moniae isolate [86], leading to concerns about the possibility of
acquisition of MDR Enterobacteriaceae.
In contrast to vancomycin-resistant E. faecalis, which can be
treated with ampicillin or the combination of ampicillin plus
gentamicin, the treatment of vancomycin-resistant E. faecium is
highly problematic. An E. faecium strain is deﬁned as ampicil-
lin-resistant if it is able to grow in 16 mg/L of ampicillin.
However, strains with ampicillin MIC lower than 100 mg/L can
be treated with high doses of the drug [87]. Other drugs
available for the treatment of vancomycin-resistant E. faecium
with high MIC for ampicillin are ﬂuoroquinolones, daptomycin,
linezolid, tigecycline, tetracycline and quinupristin-dalfopristin
(Table 1), given that aminoglycosides are inactive against
enterococci if no inhibitor of the cell wall is administered
(due to the low permeability of the enterococcal wall).
Teicoplanin may be used for the treatment of VanB-type
enterococci. However, the description of a case in which
teicoplanin resistance developed during treatment raises con-
cerns about the use of this drug for VanB E. faecium [88].
Although only daptomycin is bactericidal against VRE, linezolid
has also been widely used for the treatment of VRE bactera-
emia. It should be noted that a recent report of a new
mechanism of resistance to daptomycin in VRE, which appeared
during the treatment of bloodstream infections, has raised
concerns regarding the treatment of this microorganism [89]. A
recent meta-analysis on the comparison of the outcomes of
VRE bacteraemia treated with daptomycin or linezolid showed
that patients treated with daptomycin had higher 30-day
all-cause and overall mortality, infection-related mortality and
relapse rates compared with those treated with linezolid [90].
For monomicrobial non-bacteraemic VRE infections in SOT
patients, we recommend the use of linezolid, quinupristin-
dalfopristin or daptomycin. Daptomycin is inactivated by lung
surfactant [91]. Clinical trials for the treatment of pneumonia
showed that daptomycin failed to show non-inferiority against
comparators [92], and breakthrough pneumonia due to
daptomycin-susceptible strains may appear during treatment
with daptomycin [93]. As several meta-analyses from clinical
trials have reported an increased mortality for tigecycline vs.
comparators [94–97], we do not recommend this drug for
the treatment of monomicrobial infections with VRE. How-
ever, tigecycline could be a good choice for treating
polymicrobial infections involving VRE with other MDR
pathogens (i.e. carbapenemase-producing Enterobacteria-
ceae), a frequent situation in tertiary peritonitis with abdom-
inal collections. Finally, a similar see-saw effect to that
detected with the combination of oxacillin plus daptomycin in
MRSA has been shown with the combined use of ampicillin
plus daptomycin for VRE [98]. Therefore, in the case of
persistent and refractory bacteraemia with vancomycin-resis-
tant E. faecium, the combination of ampicillin plus daptomycin
should be tried.
Gram-negative bacteria
MDR-enterobacteriaceae.
Recommendations for the management of ESBL-,
ampC- or carbapenemase-producing Gram-negative
bacilli in solid organ transplant patients
 Screening of bowel colonization with extended-spectrum
betalactamases (ESBL)-, ampC- or carbapenemase-produc-
ing Gram-negative bacilli in patients awaiting solid organ
transplantation is not recommended in a scenario of
endemic infection. (B-III) However, in a situation of
outbreak, active screening cultures and contact precautions
in colonized patients are recommended (B-II).
 Intestinal decolonization of colonized patients with MDR
Enterobacteriaceae prior to transplantation is not recom-
mended because of its poor efﬁcacy in the long term. (C-II)
However, it may be evaluated during outbreaks (C-III).
 While in most cases ESBL-producing E. coli do not need
single-bed isolation, ESBL-producing K. pneumoniae and
Enterobacteriaceae producing derepressed ampC b-lacta-
mases or carbapenemases require single-bed isolation and
contact precautions (B-II).
 For the treatment of ESBL- or derepressed ampC b-lac-
tamase-producing Enterobacteriaceae infections in hospital-
ized SOT patients, we recommend the use of ertapenem
when the strain is susceptible, instead of imipenem,
meropenem or doripenem, for ecological reasons (B-III).
 The cornerstone of the treatment of carbapenemase-pro-
ducing Enterobacteriaceae is colistin or polymyxin B. In most
cases, combination antibiotic therapy with tigecycline,
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aminoglycosides, fosfomycin and/or carbapenems is
desirable (B-III).
Cephalosporin-resistant Enterobacteriaceae due to the
production of extended-spectrum beta-lactamases (ESBL) or
inducible chromosomal beta-lactamases (ampC) are increasing
worldwide as causes of infection in hospitalized and commu-
nity patients. E. coli and Klebsiella pneumoniae are the most
important pathogens producing extended-spectrum beta-lac-
tamases (ESBL), and Enterobacter spp., Citrobacter freundii and
Morganella morganii usually express inducible chromosomal
beta-lactamases (ampC). The typical phenotype of these
pathogens includes resistance to penicillins and cephalosporins
and susceptibility to carbapenems. As MDR pathogens, these
microorganisms typically carry additional mechanisms of
resistance, such as DNA gyrase mutations conferring resis-
tance to quinolones, deﬁcient expression of porins, and so on.
Other active antibiotics include tigecycline, aminoglycosides
and colistin (Table 1). ESBL-producing E. coli are usually
susceptible to nitrofurantoin; however, most strains of Klebsi-
ella spp. are resistant to this antibiotic. In Europe, there is a
high variability in the prevalence of MDR Enterobacteriaceae.
Taking invasive infections with E. coli resistant to third-gener-
ation cephalosporins as the reference, we found a prevalence
of 25–50% in Italy and Romania, 10–25% in Portugal, Spain,
France, the United Kingdom and others, and prevalences of 1–
5% in Sweden and Norway (http://www.ecdc.europa.eu/en/
publications/Publications/antimicrobial-resistance-surveil-
lance-europe-2012.pdf; accessed 15 May 2014).
One of the most important risk factors for ESBL- or
ampC-producing Enterobacteriaceae infection is prior bowel
colonization. One study of an intensive care unit outbreak of
ESBL-producing K. pneumoniae showed a 38% incidence of
colonization, with the most important risk factors being clinical
severity at admission, arterial catheterization, parenteral
nutrition, urinary catheterization, mechanical ventilation and
previous antibiotic treatment [99]. Bowel colonization with
ESBL-producing Enterobacteriaceae in patients at risk
increased from 1.5% in 2000 to 3.5% in 2005, a trend that is
similar for SOT patients [100]. The incidence of ESBL-pro-
ducing Enterobacteriaceae bloodstream infection increases
proportionally with the prevalence of bowel colonization
[100]. In one study the incidence of pre-transplant colonization
with ESBL-producing Enterobacteriaceae in patients
undergoing liver transplantation reached 16%, with previous
ESBL infection, hospital admission or antibiotic treatment and
more advanced liver disease being risk factors for colonization
[101]. In addition, in a study of hospitalized patients, renal
transplantation was an independent risk factor for developing
bacteraemic infection with ESBL-producing E. coli or Klebsiella
spp [102]. Moreover, patients admitted to a renal transplant
unit had a higher risk of infection by ESBL-producing enteric
bacilli with quinolone-associated resistance [103].
In the paediatric renal transplantation population, ESBL-
producing E. coli is the most frequent aetiological agent of
infection, especially of the urinary tract [104]. Although data
are scarce, renal transplant recipients seem to be at a higher
risk of infection with these bacteria, with an incidence of 12%,
especially in cases of simultaneous pancreas transplantation,
previous use of antibiotics, post-transplant dialysis and
post-transplant urinary obstruction [105]. Most ESBL- or
ampC-producing Gram-negative rods in patients with renal
transplantation are due to urinary tract infection (70%),
although surgical-site infection is another possible source
[105]. The frequency of urinary tract infections with ESBL-pro-
ducing bacteria in non-renal transplant patients is lower, but
one multicentre study reported a prevalence of 23% in liver,
heart and lung transplant patients [106]. The overall incidence
of ESBL-producing K. pneumoniae infection in the liver was
lower than in renal transplant recipients (7% vs. 11%,
respectively) [107]. In heart and lung transplant patients, the
sources of ESBL infections include bacteraemia, urinary tract
infections, pneumonia, central venous catheter-associated
infection and wound infections, but the overall incidence was
lower (2.2% and 5.5%, respectively) [108].
In recent years, infection with carbapenemase-producing
Enterobacteriaceae, especially K. pneumoniae (KPC), has
emerged as a global threat in SOT patients. Like ESBL or
derepressed chromosomal b-lactamases, carbapenemase inac-
tivates penicillins and cephalosporins, but also inactivates
carbapenems. In vitro susceptibility data from numerous studies
indicate that colistin, tigecycline and fosfomycin are the most
effective antibacterial agents against KPC-producing Entero-
bacteriaceae [109]. A single-centre study including 17 SOT
patients with KPC-producing Enterobacteriaceae infection
(mainly liver and intestinal transplantation) showed that the
main sources of the infection were intra-abdominal collections
and the biliary tract [110]. Persistent bacteraemia was very
frequent (one patient had persistent bacteraemia for more
than 300 days) and more than 70% of patients had the same
clone [110]. In contrast to liver and small-bowel transplanta-
tion, KPC-producing Enterobacteriaceae in renal transplant
patients usually causes urinary tract infections [111,112].
Interestingly, the development of necrotizing soft tissue
infections with KPC has been reported in liver transplant
patients [113], as in the case of highly-virulent genotype K1 of
K. pneumoniae in Asia [114]. KPC-producing K. pneumoniae can
be also transmitted from donor to recipient, although an
appropriate antimicrobial prophylaxis for the recipient can
prevent the development of infection [115]. As described for
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ESBL-producing Enterobacteriaceae, intestinal carriage of
carbapenemase-producing K. pneumoniae (carbapenemase
type 2, KPC-2-KP) was associated with a higher risk of
infection, with a high percentage of patients suffering blood-
stream infection, after liver transplantation [116].
The best prevention strategy for these infections is to apply
the measures recommended for hospitalized patients, such as
hand washing. While ESBL-producing K. pneumoniae strains are
highly transmissible, it seems that most ESBL-producing E. coli
strains are much less contagious, and so many centres do not
apply isolation measures in the case of patients infected with
ESBL-producing E. coli [117,118]. Patients infected with
ESBL-K. pneumoniae and carbapenemase-producing Enterobac-
teriaceae must always be admitted under contact isolation
(Table 2). We do not recommend active surveillance to detect
colonization with ESBL or ampC-producing Enterobacteria-
ceae. However, active surveillance, when accompanied by
implementation of contact precautions for colonized patients,
daily decontamination of environmental surfaces and cohorting
of patient care staff, has led to major reductions in the
carbapenem-resistant infection rate not only for outbreaks but
also in the endemic setting [119–121]. Little information is
available about the usefulness of intestinal decolonization in
organ transplant patients. In a multicentre observational study,
the use of ﬂuoroquinolones did not protect liver transplant
patients from developing early bacterial infections [122]. In
another study, the use of oral gentamicin and oral polymyxin E
was able to reduce colonization with carbapenemase-produc-
ing K. pneumoniae [123]. However, no study has proved that a
strategy of intestinal decolonization reduces the incidence of
infection with ESBL-, ampC- or carbapenamase-producing
Gram-negative bacilli. Therefore, in scenarios with endemic
infections with ESBL-producing Enterobacteriaceae, active
screening cultures to detect colonized patients are not
recommended. During outbreaks of infections caused by
ESBL-producing Enterobacteriaceae or in any situation (ende-
mic or outbreaks) of infections with carbapenemase-producing
Enterobacteriaceae, active surveillance cultures and contact
precautions are strongly recommended [118].
Carbapenems are the cornerstone of treatment for ESBL or
derepressed chromosomal betalactamase-producing Entero-
bacteriaceae. ESBL-producing strains of E. coli and Klebsiella spp.
are often resistant to quinolones and cotrimoxazole [124,125]
and usually no oral active antibiotic is available to complete the
treatment after hospital discharge. When choosing a carbape-
nem for the treatment of these infections it should be borne in
mind that the use of ertapenem may allow downscaling of the
use of imipenem and ciproﬂoxacin and that this can improve the
local susceptibility of non-fermentative Gram-negative bacilli
[126]. However, in recent years, an increase in the incidence of
ertapenem-resistant K. pneumoniae strains due to porin deﬁ-
ciency has been detected [127,128], which may produce
outbreaks in intensive care units [129]. Although prolonged in
vitro exposure to ertapenem may lead to the development of
porin-deﬁcient subpopulations of E. coli [130], this has not yet
been associated with clinical consequences [131]. There is no
evidence in favour of combination antibiotic therapy for the
treatment of ESBL or chromosomic betalactamase-producing
Enterobacteriaceae, although adding an aminoglycoside to
carbapenem in haemodynamically unstable or critically ill
patients seems a reasonable strategy. For the treatment of
cystitis caused by ESBL-producing E. coli, amoxicillin-clavulanate
and fosfomycin had a clinical efﬁcacy of 84% and 93%,
respectively, when the isolate showed susceptibility to those
drugs [132]. Other options for the treatment of these MDR
pathogens include tigecycline, cotrimoxazole, quinolones and
nitrofurantoin in the case of proven susceptibility.
In contrast to ESBL- or ampC-producing Enterobacteria-
ceae, most physicians use combination antibiotic therapy
against carbapenemase-producing Enterobacteriaceae
[110,112]. Colistin is the most active agent against these
strains and should be considered the basis of treatment in
most patients [133]. Tigecycline could represent an optimal
choice for patients with co-infection with additional MDR
pathogens (e.g. VRE or MRSA). Aminoglycosides, fosfomycin
and even high-dose carbapenems [110,112,134] should be
evaluated for the use of combination antibiotic therapy.
Non-fermentative Gram-negative bacilli.
Recommendations for the management of non-fer-
mentative Gram-negative bacilli infection in SOT
patients
 Pre-transplantation lung colonization by MDR/XDR P. aeru-
ginosa (B-II) or B. cenocepacia (B-III) is not an absolute
contraindication for lung transplantation. If present, this
colonization should be evaluated together with other
co-morbidities to assess whether their combination might
lead to unacceptably high post-transplant mortality.
 To avoid colonization by non-fermenters, antibiotic thera-
pies should be used with parsimony, and contact between
patients both pre- and post-transplantation should be
avoided (B-II).
 Treatment of MDR/XDR non-fermenters should include
combination therapies using two to three classes of
antibiotics based on resistance phenotypes (B-II).
 Time-dependent antibiotics (beta-lactam) should be given
as prolonged or continuous infusion, whereas concen-
tration-dependent antibiotics (aminoglycosides and ﬂuor-
oquinolones) should be given in high once-daily doses
(B-II).
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Pseudomonas aeruginosa is a signiﬁcant nosocomial pathogen
in all types of SOT recipients, being responsible for early
post-transplant pneumonia and bacteraemia. Signiﬁcantly, the
frequency of MDR, XDR or PR isolates is higher in SOT
recipients than in the non-transplant population, and accounts
for 50% of the P. aeruginosa bloodstream isolates [135,136].
The risk of infection is highest in lung transplant recipients,
because more than half of cystic-ﬁbrosis lung transplant
candidates are colonized before transplantation by MDR or
XDR P. aeruginosa, and up to 75% are colonized thereafter
[137]. Importantly, however, pre-transplant colonization of
lung transplant candidates by MDR/XDR P. aeruginosa does
not impact overall survival and should not contraindicate lung
transplantation [138,139]; it should be included together with
other co-morbidities in a comprehensive evaluation. Coloni-
zation and infections by other non-fermenters such as
Burkholderia, Stenotrophomonas and Achromobacter species
remain less frequent. While the data on Stenotrophomonas
and Achromobacter from SOT recipients are too scarce to
determine their particular pathogenicity in this population,
Burkolderia species and especially B. cenocepacia (genomovar
III) are clearly associated with reduced survival rates in lung
transplant recipients [140,141]. Reports of unacceptably high
fatality rates of lung transplant recipients colonized by XDR
B. cenocepacia have accumulated, leading to recommendations
of extreme caution and adequate patient information before
accepting these patients for lung transplantation. As adequate
identiﬁcation and resistance proﬁle determination may be
challenging, these strains should be evaluated by laboratories
using both conventional (OFPBL agar, PC agar, BCSA) and
molecular identiﬁcation techniques.
Similarly to MDR Enterobacteriaceae, there is a high
variability in the prevalence of MDR P. aeruginosa in Europe.
Taking invasive infections with carbapenem-resistant P. aeru-
ginosa as the reference, we found a prevalence of more than
50% in Romania, 25–50% in Italy, Greece, Bulgaria and
Hungary, and 5–10% in the United Kingdom, Sweden, Norway
and Finland (http://www.ecdc.europa.eu/en/publications/Publi
cations/antimicrobial-resistance-surveillance-europe-2012.pdf;
accessed 15 May 2014).
To avoid colonization by these isolates, particular care
should be taken both pre- and post-transplantation to
reduce exposure to antibiotic therapies. If these therapies
are required, their duration should be kept as short as
possible. To avoid transmission of epidemic strains such as
the P. aeruginosa Liverpool strain, contact between patients
should be restricted [142]. Contact isolation is indicated
for transplant recipients harbouring MDR/XDR P. aerugin-
osa and B. cepacia. As nebulizers can potentially transmit
B. cepacia, the use of these devices should include strict
hygiene measures. Sinus surgery (endoscopic fronto-sphe-
no-ethmoidectomy), potentially combined with sinonasal
and bronchial colistin inhalation, has been suggested as a
way to prevent post-lung transplant recolonization by
P. aeruginosa from a sinus reservoir [143,144]. However,
the experience with such aggressive management remains
controversial, and for the moment it cannot be routinely
recommended [145].
Infection control policies do not differ from those recom-
mended for the general population (Table 2). SOT patients
infected or colonized with MDR/XDR non-fermentative bacilli
other than B. cepacea should be isolated. In all cases, hand
hygiene measures and other contact precautions, and envi-
ronment cleaning, are recommended.
Treatment data speciﬁc to transplant recipients are lacking.
In all situations time-dependent betalactam antibiotics (piper-
acillin tazobactam, ceftazidime, meropenem and doripenem)
should be given, using prolonged or continuous infusion in
order to optimize pharmacokinetic parameters [146,147]. In
contrast, concentration-dependent antibiotics (aminoglyco-
sides and ﬂuoroquinolones) should be given in high once-daily
doses. For MDR/XDR P. aeruginosa infections, combination
therapies including two to three different antibiotic classes
(beta-lactam + aminoglycoside  ﬂuoroquinolone) are rec-
ommended for 10–14 days [139,148]. Clinical experience with
novel combinations including systemic colistin, fosfomycin and
rifampicin is scarce. Colistin or beta-lactams given as adjunctive
aerosolized therapies have shown promising results and can be
used in difﬁcult cases [149,150]. For MDR/XDR B. cepacia
infections, triple combinations including meropenem, amino-
glycosides and either ceftazidime or trimethoprim sulfameth-
oxazole are recommended. The clinical signiﬁcance of MDR/
XDR A. xylosoxidans is questionable. Treatment should there-
fore be restricted to chronically colonized/infected patients
with clear clinical decline, using combination therapies including
piperacillin-tazobactam, carbapenems and/or trimethoprim
sulfamethoxazole. MDR/XDR Stenotrophomonas infections
require high-dose trimethoprim sulfamethoxazole combined
with ceftazidime, and levoﬂoxacin. Depending on the resistance
proﬁle, alternative combinations might also include bacterio-
static compounds such as doxycycline and tigecycline.
Antimicrobial Spectrum, Interactions and
Adverse Effects of Less Frequently Used
Antibiotics for Treatment of MDR
Pathogens in SOT Patients
A great deal of information is available on the toxicity, drug
interactions and adverse effects in SOT patients of the most
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common antibiotics (betalactams, aminoglycosides, cotrimox-
azole, etc.). However, there is a subgroup of antibiotics – both
new and old – in which the experience in SOT patients is very
limited, but which are being increasingly used for the treatment
of MDR infections. These antibiotics include ceftaroline,
tigecycline, daptomycin, linezolid, fosfomycin and colistin
(Table 3).
Ceftaroline-fosamil is a new cephalosporin approved in the
United States and in Europe for the treatment of acute
bacterial skin and skin structure infections and commu-
nity-acquired bacterial pneumonia. Ceftaroline-fosamil is a
prodrug of the active metabolite, ceftaroline. Its mechanism of
action is by binding bacterial penicillin-binding proteins (PBPs),
but, in contrast to the rest of the betalactams, ceftaroline has
high afﬁnity for binding PBP 2A [151]. Its microbiological
spectra include Gram-positive (including MRSA, MDR S. pneu-
moniae and vancomycin-resistant E. faecalis) and Gram- nega-
tive bacteria. Ceftaroline does not possess activity against
E. faecium. The incidence of adverse effects for ceftaroline in
clinical trials has been low and no relevant drug interactions
have been described. Alterations in liver function tests
occurred in 2.5% of patients who received ceftaroline in phase
3 clinical trials [152]. Around 10% of patients treated with
ceftaroline-fosamil may experience seroconversion from a
negative to a positive direct Coombs’ test [153]. In SOT
patients with MDR infections, ceftaroline may represent a
good option for the treatment of invasive infections with
MRSA, although no published evidence is available at present.
Tigecycline belongs to the new glycylcycline family and it is
structurally similar to the tetracyclines. This antibiotic pos-
sesses an extended antimicrobial spectrum which includes
most MDR pathogens: MRSA, VRE, Acinetobacter baumannii,
Stenotrophomonas maltophilia and MDR Enterobacteriaceae
(including ESBL-, derepressed AmpC- and carbapenemase-pro-
ducing strains) [154]. Tigecycline lacks activity against Pseudo-
monas aeruginosa. Its volume of distribution is very high, with
good concentrations in tissue and low concentrations in
serum, and only 15% of the drug is excreted unaltered in the
urine. These two pharmacokinetic properties have triggered a
debate on the appropriateness of tigecycline for the treatment
of urinary tract infections and bacteraemic patients [155]. As
commented above (treatment of VRE infections), several
meta-analyses of clinical trials have reported increased mor-
tality in tigecycline vs. comparators for the treatment of
diverse sources of infection. For this reason, tigecycline should
be reserved for the treatment of MDR pathogens, especially in
the case of polymicrobial infections. Most of the published
experience of its use in SOT patients comes from the
description of cases with carbapenemase-producing Entero-
bacteriaceae [110–113,115,134]. No serious adverse effects in
SOT patients have been described with the use of tigecycline.
Increased bioavailability of cyclosporine has been reported
upon concomitant treatment with tigecycline [156].
Daptomycin is a cyclic lipoglycopeptide with rapid bacte-
ricidal effect against Gram-positive bacteria, causing depolar-
ization of the cytoplasmic membrane after irreversible binding
in a calcium-dependent manner. In SOT patients, the most
frequent bacterial targets for the use of daptomycin are
S. aureus and VRE. The information available regarding the
safety and efﬁcacy of daptomycin in SOT patients is limited to
case reports [157–160]. In the major clinical trials with
daptomycin, the drug was well tolerated and its proﬁle of
adverse effects was similar to that of the comparator drugs
[67,161]. In general, daptomycin does not alter liver function
tests, but cases of liver toxicity related to its use have been
reported [162,163]. In a randomized clinical trial, daptomycin
was less nephrotoxic than the comparator [67]. Its most
characteristic adverse effect is skeletal muscle toxicity. In
most patients, muscle toxicity consists of asymptomatic
increases in the creatine kinase serum levels, which return
to normal after discontinuation of the treatment. Conse-
quently, monitoring creatine kinase serum levels during
treatment with daptomycin is recommended. Discontinuation
of treatment with statins is mandatory prior to the use of
daptomycin, because the concomitant use of the two drugs
can increase the incidence of muscle toxicity. As noted
above, daptomycin is inactivated by the lung surfactant, and
does not have a therapeutic effect on low-tract respiratory
infections. No signiﬁcant interactions with immunosuppres-
sants have been reported.
Linezolid belongs to the new family of oxazolidinones and is
an active agent against Gram-positive pathogens. As a result, it
can represent an alternative for the treatment of MRSA and
vancomycin-resistant enterococci. Linezolid does not cause
direct nephrotoxicity, but several cases of acute interstitial
nephritis have been described [164,165], one of them in a renal
transplant patient [166]. A study performed in 46 liver
transplant patients with Gram-positive bacterial infections
treated with linezolid during a mean of 11 days showed
neither signiﬁcant haematological abnormalities nor any other
relevant side-effects [167]. A subgroup analysis of patients who
received treatment for 15 or more days did not show any
relevant side-effects [167]. One multicentre trial of compas-
sionate use of linezolid for the treatment of VRE included 85
SOT patients with demonstrated VRE infection (liver, kidney,
heart, lung and multivisceral), of whom 43 were bacteraemic,
and reported an incidence of thrombocytopenia of 4.7% and
decreased leukocyte count in 3.5% of patients [168]. No
relevant interactions with immunosuppressants have been
reported with linezolid.
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Fosfomycin may be an alternative for the treatment of
MRSA, vancomycin-resistant enterococci, ESBL-producing en-
terobacteriaceae and MDR P. aeruginosa infections in organ
transplant patients. Fosfomycin can also act synergistically with
amoxicillin, daptomycin and linezolid against vancomycin-resis-
tant E. faecium [169]. Adverse effects related to intravenous
fosfomycin-disodium are rare. The most common and the
most relevant is a high-sodium intake, resulting in water
retention, oedema, ascites and heart failure in susceptible
patients [170]. Oral fosfomycin may be a good option for the
treatment of MDR bacteria causing urinary tract infection; it is
generally well tolerated, although nearly 10% of patients may
develop diarrhoea. One retrospective study of 14 episodes of
urinary infections in nine renal transplant patients treated with
fosfomycin (3 g per day for 1–7 days) showed that the drug
was well tolerated, although the overall bacterial clearance
rate at 3 months was low (31%) and the incidence of
recurrence was high (54%) [171]. No relevant interactions
with immunosuppressants have been described.
The two main adverse effects of intravenous administration
of colistin are renal and neurological toxicity. The mechanism
of renal toxicity of colistin is not fully understood but in vitro
electrophysiological studies demonstrate that the drug is
directly toxic to urothelium by increasing transepithelial
conduction, especially during long-term use [172]. The
incidence of colistin-related nephrotoxicity varies widely
depending on the series (0–54.5%) [173], but several studies
have shown that it mainly depends on the basal renal function,
and is higher in patients with altered renal function [174–176].
In the transplant setting, in a recently published study of 92
transplant patients treated with polymyxin, renal toxicity
appeared in nearly a third of the sample, and was correlated
with the duration of therapy [177]. Special attention must be
paid to the association of polymyxin B or colistin with
aminoglycosides, which may result in a higher risk of renal
toxicity [178]. Colistin-related neurological adverse effects
probably occur because of a similar renal toxicity mechanism.
Colistin can modify conduction of neurons, which are rich in
lipids, resulting in visual disturbances, confusion, peripheral
paresthesias and seizures [179]. The most life-threatening
neurological adverse effect related to the use of colistin is
neuromuscular blockade, which resembles myasthenia gravis
and may cause respiratory muscle paralysis and apnoea
[180,181]. No speciﬁc or relevant interactions of colistin with
immunosuppressants have been described. In one prospective
study of colistin-treated patients, slight increases in aspartate
amino-transferase were observed after prolonged treatments
[182]. Another important point is that there are no clinical
breakpoints for polymyxins or colistin against Enterobacteri-
aceae, and the pharmacokinetics of the drug has not been fully
established. Thus, it is very important to know the appropriate
dosage of these drugs in order to maintain the balance
between efﬁcacy and adverse side-effects. Table 4 shows the
recommended dosage of polymyxin and the two main
presentations of colistimethate sodium.
Pivmecillinam is a pro-drug of mecillinam, a betalactam with
speciﬁc activity against Gram-negative bacteria. Given orally, it
achieves bacteriological cure rates higher than 90% in patients
with low-tract urinary tract infections [183]. Although pivme-
cillinam has poor activity against Gram-positive bacteria, it has
good activity against ESBL-producing E. coli [184] and can
represent an alternative to carbapenems for the treatment of
recurrent cystitis due by this bacterium in kidney transplant
recipients. Another option for the treatment of MDR
Gram-negative bacteria is temocillin, a derivate of ticarcillin.
Developed during the 1980s, temocillin was abandoned because
of its lack of activity against Gram-positive bacteria, anaerobes
and P. aeruginosa [185]. However, this drug is active againstmost
ESBL, AmpC and KPC-producing Enterobacteriaeae [186].
Temocillin is, however, inactivated by other carbapenemases.
Common Difﬁcult-to-Treat Bacterial
Infections Associated With MDR After SOT
Recommendations for the management of difﬁ-
cult-to-treat infections in SOT patients
 Antibiotic therapy for complex or recurrent infections in
SOT patients should be used with caution, especially when
used as prophylaxis. Care should be taken to avoid treating
asymptomatic patients, in order to reduce the possibility of
infection with MDR pathogens (B-III).
 When treating patients with suppurating collections
(abdominal abscesses, infected bilomas), surgical manage-
ment or drainage of the collections is desirable when
possible, as the likelihood of curing these infections conser-
vatively is very low (B-III).
 Recurrent cholangitis in liver transplant patients is usually
associated with biliary strictures. Most cases beneﬁt from
surgical or percutaneous treatment to restore the biliary
tree (B-III).
 Recurrent urinary tract infection is a common problem in
renal transplant patients and, although many patients do not
have structural lesions, a morphological and/or dynamic
study of the urinary tract should be performed in all patients
(B-III). The use of antibiotic prophylaxis for recurrent
urinary tract infection (UTI) after renal transplantation is not
supported by published evidence so the decision to give it or
not depends on the experience of the treating physician
(C-III).
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 Initial management of mediastinitis after heart transplanta-
tion includes aggressive surgical debridement and antibiotic
treatment should be active against Gram-positive pathogens,
including MDR strains, depending on the local epidemiology
(B-III).
 Recurrent tracheobronchial infections after lung transplan-
tation are usually associated with strictures of the bronchial
anastomosis. Little evidence is available regarding the
management of this situation, but many centres use aero-
solized antibiotics to treat infections with low risk of
invasion and reserve systemic therapies for more severe
infections (C-III).
Some patients with SOT will develop difﬁcult-to-treat
infections, which in most cases are directly related to the
surgical procedure. In many cases, these infections tend to
reoccur and, consequently, the patients are exposed to
repeated courses of antibiotics. This can lead to the
development of recurrent MDR bacterial infections. Thus,
antibiotic therapy for complex or recurrent infections in SOT
patients should be used with caution. This is especially
relevant when we give prophylactic antibiotics or when we
treat asymptomatic patients. Table 5 summarizes the most
frequent conditions associated with recurrent infections after
SOT.
Infected bilomas
Infected bilomas can occur in around 10% of patients with
orthotopic liver transplantation [187], causing high morbidity
and resource consumption due to frequent hospital readmis-
sions, need for re-transplantation and mortality [187,188].
When infected biloma coexists with hepatic artery thrombosis,
the best therapeutic approach for its management in many
TABLE 4. Recommended dosage of polymyxin B and colistimethate sodium, either for intravenous or inhalation therapy
Polymyxin B
Colistimethate sodium (CMS)
Colomycin injection
Colistimethate sodium (CMS)
Coly-Mycin M Parenteral
Composition of vials 500 000 units (c. 50 mg) 500 000 IU (40 mg)
1 000 000 IU (80 mg)
2 000 000 IU (120 mg)
150 mg colistin base activity
(400 mg CMS)
Recommended dose for patients
with normal renal function
15 000–25 000 IU/kg/day in
one daily or two divided doses
(equivalent to 1.5–2.5 g)
≤60 kg, 50 000–75 000 IU/kg/day in
three divided
doses (equivalent to 4–6 mg/kg/
day CMS)
60 kg, 1–2 million IU three times a
day (equivalent to 80–160 mg CMS
three times per day)
Maximum dose of 6 million IU in 24 h
2.5–5.0 mg/kg/day colistin
base activity in 2–4 doses
(equivalent to c. 6.67–13.3 mg/
kg/day CMS)
Recommended dose adjustment
in patients with renal impairment
According to creatinine
clearance (CLCR):
 CLCR of 30–80 mL/min,
loading dose of 2.5 mg/kg/day on
the ﬁrst day and then 1.0–1.5 mg/kg/day
 CLCR <30 mL/min, loading dose of
2.5 mg/kg/day on the ﬁrst day and then
1.0–1.5 mg/kg/day every 2–3 days
 Anuric patients, loading dose of
2.5 mg/kg/day on the ﬁrst day and
then 1.0–1.5 mg/kg/day every 5–7 days
According to creatinine clearance
(CLCR) and over 60 kg bodyweight:
 CLCR 20–50 mL/min,
1–2 million IU every 12 h
 CLCR 10–20 mL/min,
1 million IU every 12–18 h
 CLCR <10 mL/min,
1 million IU every 18–24 h
According to creatinine clearance
(CLCR) and over 60 kg
bodyweight:
 CLCR 50–80 mL/min,
75–115 mg every 12 h
 CLCR 30–50 mL/min,
66–150 every 12–24 h
 CLCR 10–30 mL/min,
100–150 every 36 h
Recommended dose for
inhalation therapy
2.5 mg/kg daily in divided doses
every 6 h (respiratory infections)
to 500 000 IU twice a day (pneumonia)
1–2 million units twice daily,
dissolved in 2–4 mL of water
for injections or 0.9% sodium
chloride intravenous infusion
for use in a nebuliser
1–2 million IU, 2 or 3 times daily,
diluting the appropriate dose in
2–4 mL of preservative-free 0.9%
sodium chloride injection, sterile
water, or a mixture of 0.9%
sodium chloride injection and
sterile water for use in a
nebuliser
TABLE 5. Common difﬁcult-to-treat syndromes associated
with recurrent infection leading to a higher risk of selection
or superinfection with MDR pathogens in SOT patients
Syndrome Type of transplantation
Recurrent urinary
tract infections
Renal transplantation
Simultaneous kidney-pancreas
transplantation
Cyst infections Renal transplantation for
polycystic renal disease and/
or coexisting liver cysts
Infected biloma Liver transplantation
Multivisceral transplantation
Recurrent cholangitis Liver transplantation
Multivisceral transplantation
Tertiary peritonitis and
abdominal abscesses
Pancreas transplantation
Liver transplantation
Intestinal/multivisceral transplantation
Mediastinitis Heart transplantation
Lung transplantation
Combined heart-lung transplantation
Recurrent respiratory
tract infection
Lung transplantation
Combined heart-lung transplantation
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cases is liver re-transplantation, as the likelihood of cure by
applying conservative treatments is very low [187]. Gram-po-
sitive bacteria are the main causes of infected bilomas
(including coagulase-negative staphylococci and enterococci),
followed by Candida spp., enterobacteriaceae and Pseudomonas
aeruginosa [187]. Conservative treatment includes percutane-
ous catheter drainage and single aspiration (for extrahepatic
bilomas) as well as appropriate antimicrobial treatment. The
duration of antibiotic treatment in conservative management
of infected bilomas has not been established, but it should be
probably prolonged for 4–6 weeks, taking into account the
improvement of patient’s clinical symptoms, radiological stud-
ies and inﬂammatory markers in blood analysis. However,
prolonged or cyclic broad-spectrum antibiotics for infected
bilomas may produce superinfection or selection of MDR
bacteria. Therefore, antimicrobial treatment for infected
bilomas needs to be used with caution. In the case of
methicillin-resistant coagulase-negative staphylococci or
vancomycin-resistant enterococci infection, linezolid and dap-
tomycin may be a good treatment option as both drugs achieve
excellent biliary pharmacodynamic exposure [189,190]. For
the treatment of Gram-negative infected bilomas, imipenem
[191], meropenem [192] and ertapenem [193] achieve optimal
concentrations in bile after systemic administration. No
information is available on the bile concentrations of colistin
after intravenous treatment. Tigecycline achieves high concen-
trations in bile [194] and can be used for the treatment of
infected bilomas with carbapenemase-producing Enterobacte-
riaceae. For the treatment of infected bilomas with Candida
spp., ﬂuconazole is the drug of choice because of its good
concentration in bile [195] and good safety proﬁle. Vorico-
nazole probably also achieves good concentrations in bile, as it
was demonstrated to have optimal concentrations in the liver
of eight deceased patients on autopsy [196].
Recurrent cholangitis
Chronic recurrent bacterial cholangitis may appear in liver
transplant patients with structural lesions of the biliary tree. The
most frequent structural biliary lesions include bile leak,
anastomotic and non-anastomotic strictures and ampullary
dysfunction [197]. Some patients, especially recipients of a liver
from a cardiac-death donor, may develop ischaemic cholangi-
opathy leading to non-anastomotic strictures [29]. Other less
frequent complications such as recurrence of a primary
sclerosing cholangitis in the liver graft and secondary sclerosing
cholangitis can produce structural lesions in the biliary tree.
Living donor liver transplantation also has a high incidence of
biliary complications (for example, leaks and stenosis) becauseof
certain features of the surgical technique. This complicationmay
increase both morbidity and resource consumption in some
patients. However, few recommendations or case descriptions
are currently available. The case reports that have been
published describe patients with multiple episodes of bacterial
cholangitis requiring readmission and the use of broad-spectrum
antibiotics [198],whichmay increase bile and bowel colonization
with MDR pathogens. When a liver transplant patient develops
recurrent cholangitis, we must always search for a biliary
stenosis and try to resolve it surgically or by percutaneous
dilatation. Little information is available regarding the manage-
ment of recurrent cholangitis in the setting of liver transplan-
tation, although this clinical situation may be more frequent in
daily clinical practice than the literature suggests.
Recurrent urinary tract infection
Recurrent urinary tract infection (UTI), deﬁned as three or
more episodes of symptomatic urinary tract infection over a
12-month period or two episodes in the previous 6 months
[199], is a common problem in renal transplant patients.
Febrile recurrent UTI in patients with no abnormalities in
bladder voiding such as neurogenic bladder or diabetic
cystopathy may be secondary to post-transplant vesicoureteral
reﬂux; in most of these patients, surgical correction leads to
resolution of the episodes of UTI and prolongs the life of the
graft [200]. However, most recurrent cystitis and some
recurrent febrile UTIs have no underlying anatomical altera-
tions and, consequently, should be managed medically. In
addition, recurrent UTI in renal transplantation without
vesicoureteral reﬂux may cause allograft scarring, although
no impairment of long-term graft functioning has been shown
[201]. The ﬁrst diagnostic approach in renal transplant patients
with recurrent UTI should include static or dynamic imaging
studies of the genitourinary tract in order to rule out
anatomical defects. Surgical correction of the urinary obstruc-
tion or vesico-ureteric reﬂux may cure recurrent infections in
the majority of patients. However, in many cases no underlying
anatomical or functional reason for recurrent UTI will be
identiﬁed and the dilemma of giving long-term antibiotic
prophylaxis may arise. In addition to increasing the risk of
acquiring MDR pathogens, few data regarding the efﬁcacy of
antibiotic prophylaxis in renal transplant patients with recur-
rent UTI are available. There is also a lack of information about
non-pharmacological measures, such as cranberry extract, to
prevent UTI in this population of patients.
Finally, many kidney transplant recipients have recurrent UTI
with MDR pathogens, narrowing the options for prophylaxis
with orally available antibiotics. A recently published systematic
review of the literature regarding ﬁve strategies to control
recurrent UTI in women concluded that daily low-dose
nitrofurantoin prophylaxis was the most efﬁcacious strategy
[202]. However, in patients with low glomerular ﬁltration rate
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(<60 mL/min) nitrofurantoin serum levels may increase, leading
to toxicity, and urinary concentrations decrease, leading to
treatment failures. Thus, daily low-dose nitrofurantoin prophy-
laxis should be evaluated with caution for renal transplant
patients and it should be contraindicated in most patients due to
the little information about its safety. Currently, the available
evidence does not allow making a ﬁnal recommendation on this
issue and management should be individualized.
Cyst infection
Cyst infection of the native kidney can occur in patients with
renal transplantation due to polycystic renal disease. Many
patients with polycystic disease also have liver cysts, which may
also suffer infectious complications. Around 75% of the
episodes are caused by E. coli and around 70% can be cured
with antibiotics [203]. However, some cases require surgical
drainage, especially larger infected cysts [203]. The success of
medical treatment of this complication depends mainly on the
penetration of antibiotics into the infected cysts. While
ﬂuoroquinolones, sulfamethoxazole-trimethoprim, metronida-
zole and clindamycin reach optimal concentrations inside the
cysts, betalactams and aminoglycosides have poor penetration
[204–209]. This may lead to subtherapeutic antibiotic concen-
trations in the cyst, increasing the rate of drug resistance. No
studies are available about the management of infected cysts
with MDR pathogens in renal transplant patients. However,
infected cysts with aggressive multidrug-resistant pathogens
(such as P. aeruginosa) may require surgical treatment, includ-
ing drainage or native kidney nephrectomy.
Mediastinitis
Bacterial mediastinitis is a possible complication of heart, lung
and combined heart-lung transplantation. While the incidence
of mediastinitis after cardiac surgery is estimated to be below
2% of patients, its mortality remains high (around 35%) [210].
In heart transplant patients, mediastinitis is often associated
with the use of left-ventricular assist devices [211,212]. The
majority of the cases are caused by Gram-positive bacteria
(including S. aureus and coagulase-negative staphylococci),
although around a third are caused by Gram-negative bacilli
[212]. The incidence of MDR bacteria in surgical site infections
after heart transplantation was high in one study (including
coagulase-negative staphylococci, MRSA and ESBL-producing
E. coli) [54], so we must bear in mind a possible high incidence
of MDR pathogens causing mediastinitis in heart transplant
patients. Cases of MRSA [213], vancomycin-intermediate
S. aureus [214], VRE [215] and non-fermentative bacilli [216]
have been described in Mediastinitis after heart transplantation.
The ﬁrst approach for the treatment of bacterial mediastinitis
in lung or heart transplantation is early and aggressive surgical
debridement [217]. Vacuum-assisted closure therapy com-
bined with appropriate antibiotic treatment may be useful after
surgery [218]. Choice of antibiotic therapy should be guided by
bacterial isolation and antibiogram.
Tracheobronchial bacterial infections in lung transplant
patients
The surgical procedure of lung transplantation implies the
interruption of the bronchial artery circulation. As a conse-
quence of ischaemia, the epithelium integrity is destroyed and
the mucociliary clearance impaired, leading to epithelial
sloughing, which together with bronchial hyperresponsiveness,
increased mucus production and post-surgical altered cough
reﬂexes, impairs the airway defences against pathogens [219].
Obviously, as a consequence of a limited exposure to immune
defence mechanisms and poor concentrations of a systemi-
cally-administered antibiotic in the necrotic tissues, bacterial
colonization and infection at the bronchial anastomosis is very
frequent in lung transplant patients. This unfavourable situation
is transient. Patients are at risk until collateral circulation
develops from the pulmonary artery circulation, reaching a
stable situation between 4–6 weeks post-transplantation.
During the period of high risk, most centres perform routine
bronchoscopic examinations to evaluate necrosis, purulence,
ulcerations, dehiscence and strictures, and to obtain samples
for microbiological identiﬁcation of potential pathogens at the
anastomotic site. Whereas little information on bacterial
pathogens is available in the literature, fungal bronchial
anastomotic infections leading to life-threatening bronchovas-
cular ﬁstulas have been reported [220,221]. Bacterial patho-
gens include P. aeruginosa and staphylococci [222]. Although
no published data are available, most centres use aerosolized
antibiotics (colistin and/or tobramycin) to treat these infec-
tions and reserve systemic therapies for situations where
there is risk of local invasion.
Some patients develop late sequelae that include anastomotic
strictures and bronchial stenosis that lead to long-term impair-
ment of mucus clearance and recurrent post-obstructive lung
infection. These situations frequently require balloon dilation,
laser photoresection and/or endobronchial stent placement
[223]. Moreover, whereas the highest incidence of pneumonia
after lung transplantation is during the ﬁrst month [35], at later
stages of the post-transplant period many lung recipients
develop bronchiectasis that increases the risk of recurrent
infections. In both situations, because of the frequent exposure
to antibiotics, lung transplant patients have a high risk of
colonization and subsequent infection with MDR/XDR patho-
gens (mainly P. aeruginosa and S. aureus) that become progres-
sively more difﬁcult to treat. Therefore, whereas no literature is
available to directly support this view, a judicious use of
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antibiotics is recommended, trying to treat only proven acute
infections. Combination therapies including both systemic and
aerosolized antibioticsmight reduce the risk of rapid selection of
resistant isolates. The use of antibiotics at high doses and the
optimization of pharmacokinetics by using continuous/pro-
longed infusion of beta-lactams might further be helpful. Other
strategies are based on the hypothesis that repeated and regular
antibiotic therapies could reduce the bacterial burden leading to
infection. In order to minimize the risk of selecting resistant
isolates, such therapies have been given twice weekly and always
include a full day of combination therapy with a continuous/
prolonged infusion of a betalactam and a once daily high dose of
ﬂuoroquinolone, as well as aerosolized colistin/tobramycin. This
strategy followed for up to 12 months has so far been successful
in a limited number of patients, avoiding pneumonia recurrence
without selection of resistant isolates (C. van Delden, unpub-
lished data). However in the absence of a clinical trial, this
strategy can so far not be recommended routinely.
Intra-abdominal infection and abscesses
Intra-abdominal infection is a common complication after liver,
pancreas, intestinal or multivisceral transplantation, because all
those surgeries involve manipulation of the abdominal viscera.
This complication affected 22% of patients in a study of 217
pancreas transplant recipients at a single institution and was
frequently accompanied by bloodstream infection [224]. In
pancreas transplant patients, secondary peritonitis is usually
associated with anastomotic leaks or pancreas ﬁstulae. Infec-
tion with bacteria in general and speciﬁcally surgical-site
bacterial infection occurs mainly within the ﬁrst month of
transplantation [225] but bacterial peritonitis after pancreas
transplantation may occur later, due to the development of
late anastomotic leaks [226]. Usually, secondary peritonitis
after pancreas, liver or intestinal transplantation is cured after
surgical repair of the anatomical site of the infection and with
appropriate antimicrobial therapy. However, if infection per-
sists, a shift from a pro-inﬂammatory cytokine to an
anti-inﬂammatory pattern may occur, reducing the percentage
of HLA-DR (CD 14) expressing monocytes, which culminates
in a situation of immune palsy [227]. Clinically, tertiary
peritonitis leads to an impairment of the wound healing
capacity. As many of these patients receive broad-spectrum
antibiotics, peritoneal super-infection with MDR pathogens
occurs frequently, leading ﬁnally to tertiary peritonitis. In these
patients, the risk of infection with MDR Gram-positive and
Gram-negative bacteria increases considerably [228], and
Candida spp. appear frequently as a co-pathogen.
The ﬁrst approach to the treatment of secondary and
tertiary peritonitis in SOT patients includes the identiﬁcation
and surgical repair of the leak responsible for this situation.
Antimicrobial therapy for tertiary peritonitis should be guided
by local antimicrobial resistance data and by antibiogram of
the strains isolated after surgical procedure or drainage of the
collections. Little information is available about the pharma-
cokinetics of antimicrobials in the peritoneal ﬂuid after
systemic administration, and much of it comes from case
reports or short case series. Imipenem [229], meropenem
[230], daptomycin [231], linezolid [214,232] and colistin
[233] probably reach optimal concentrations in peritoneal
ﬂuid after systemic treatments and are good options for the
treatment of peritonitis due to MDR bacteria. Other
antimicrobials such as ertapenem [234] and tigecycline [235]
reach inappropriate concentrations in peritoneal ﬂuid, and so
dose increases must be considered for the treatment of
tertiary peritonitis. Although vancomycin may reach concen-
trations above the MIC in peritoneal ﬂuid after systemic
administration in patients with peritonitis [236], its pharma-
cokinetics in peritoneal ﬂuid during prolonged treatments has
not been established. Fluconazole is the treatment of choice
for Candida spp. peritonitis [237]. Although no information
about the distribution of echinocandins in peritoneal ﬂuid is
available, some clinical trials and case series suggest that these
drugs may be an optimal treatment for non-albicans Candida
peritonitis [238,239].
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